Retatrutide is an experimental synthetic peptide that acts as an agonist at three different receptors: GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotropic peptide), and the glucagon receptor (GCGR). This combination makes it a so-called “triple agonist,” with each of these receptors involved in the regulation of metabolism, energy expenditure, and glucose homeostasis. Retatrutide is being investigated for the treatment of obesity, metabolic syndrome, and type 2 diabetes. In practice, this means that it is a substance that combines multiple effects at once – it suppresses appetite, supports energy expenditure, and improves metabolic balance.
